Please assess the completion status of the following clinical trial:

Trial Title: The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-60 years~* Diagnosis of Polycythemia Vera according to World Health Organization 2016 criteria~* Diagnosis of Polycythemia Vera including a recent bone marrow (BM) biopsy (performed within 3 years prior randomization in the study) and never treated with cytoreductive drugs~* HCT\<45%~* Ability and willingness to comply with all study requirements~* Signed written informed consent.~Exclusion Criteria:~* Any previous well documented cardiovascular PV-related events (see Appendix 1 for description)~* Previous cytoreductive drugs~* Known hypersensitivity or contraindications to the Investigational Medicinal Product (Pegylated Proline-Interferon alpha-2b) including:~evidence of severe retinopathy (e.g. cytomegalovirus retinitis, macular degeneration) or clinically relevant ophthalmological disorder (due to diabetes mellitus or hypertension); thyroid dysfunction not adequately controlled; patients tested positively with Thyroglobulin antibody and / or TPOAb at screening; documented autoimmune disease at screening or in the medical history; history or presence of depression requiring treatment with antidepressant; any risk of suicide at screening or previous suicide attempts;~* Previous exposure to a non-pegylated or pegylated interferon α~* Clinically relevant pulmonary infiltrates, pneumonia, and pneumonitis~* Systemic infections, e.g. hepatitis B, hepatitis C, or HIV at screening~* Significant liver (AST or alanine aminotransferase \> 2.5 times ULN) or renal disease (creatinine \> 2 mg/ml)~* Presence of any life-threatening condition or of any disease (e.g. cancer) that is likely to significantly shorten life expectancy~* History of active substance or alcohol abuse within the last year~* Any condition that in the opinion of the investigator would jeopardize the evaluation of efficacy or safety or be associated with poor adherence to the protocol~* Pregnant or lactating women and women\*/men of childbearing potential who are not using or are not willing to use any effective means of contraception (i.e. sexual abstinence, hormonal contraceptive, intra-uterine device, barrier method such as diaphragms or condoms, surgical methods).~  * Pregnancy test will be performed in order to ascertain negativity of human chorionic gonadotropin (β-hCG) test and confirm that childbearing women are not pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Phlebotomies + ASA (Type: ACTIVE_COMPARATOR): Conventional treatment based on phlebotomies and low dose (100 mg) of acetylsalicylic acid (ASA)
- Phlebotomies + ASA + AOP2014 (Type: EXPERIMENTAL): Conventional treatment based on phlebotomies, low dose (100 mg) of acetylsalicylic acid (ASA) plus the addition of 100 µg of Pegylated Proline-Interferon alpha-2b (AOP2014) once every 14 days (subcutaneously).

Based on this trial design, predict the completion outcome and termination type (if applicable).